Glibenclamide plus metformin combination tablets are effective, convenient and well tolerated in the treatment of type 2 diabetes mellitus

    loading  Checking for direct PDF access through Ovid

Abstract

Combination therapy with an insulin-stimulating agent (i.e. glibenclamide [glyburide]) and an insulin-sensitising agent (i.e. metformin) is an optimal and rational therapeutic first- and second-line treatment in patients with type 2 diabetes mellitus. Single-tablet glibenclamide/metformin achieves better glycaemic control than monotherapy with either agent. The improved convenience of fixed-dose glibenclamide/metformin may improve patient compliance with treatment, thereby improving glycaemic control

Related Topics

    loading  Loading Related Articles